Why do cancers have high aerobic glycolysis?

Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82

Regulation of cancer cell metabolism. Nat Rev Cancer (2011) 15.44

Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell (2007) 8.84

Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell (2011) 7.33

Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev (2009) 6.46

Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell (2010) 5.47

Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science (2009) 5.31

HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev (2009) 5.24

Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A (2010) 4.97

Mitochondria and cancer. Nat Rev Cancer (2012) 4.81

Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res (2008) 4.79

Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell (2008) 3.95

Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell (2009) 3.85

The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab (2012) 3.81

How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature (2012) 3.77

SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. Cancer Cell (2011) 3.71

Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol Biol Cell (2007) 3.54

Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol (2007) 3.51

Inferring pathway activity toward precise disease classification. PLoS Comput Biol (2008) 3.48

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A (2011) 3.48

Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer (2008) 3.39

ROS function in redox signaling and oxidative stress. Curr Biol (2014) 3.35

Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer (2011) 3.10

Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis (2013) 3.07

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell (2015) 3.03

PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol (2014) 3.02

Regional Isolation Drives Bacterial Diversification within Cystic Fibrosis Lungs. Cell Host Microbe (2015) 2.98

Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev (2011) 2.97

Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med (2011) 2.97

Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med (2011) 2.93

Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer (2012) 2.71

Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol (2006) 2.68

Acidity generated by the tumor microenvironment drives local invasion. Cancer Res (2013) 2.63

Metabolic catastrophe as a means to cancer cell death. J Cell Sci (2007) 2.58

Molecular control of bacterial death and lysis. Microbiol Mol Biol Rev (2008) 2.52

Glycogen synthase kinase 3alpha and 3beta mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1. Mol Cell Biol (2007) 2.45

Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov (2011) 2.45

Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci U S A (2007) 2.44

LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther (2009) 2.43

Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc Natl Acad Sci U S A (2007) 2.34

Transcriptional integration of mitochondrial biogenesis. Trends Endocrinol Metab (2012) 2.34

The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol (2010) 2.33

A nanoparticle-based strategy for the imaging of a broad range of tumours by nonlinear amplification of microenvironment signals. Nat Mater (2013) 2.32

Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget (2011) 2.28

Metabolic flux and the regulation of mammalian cell growth. Cell Metab (2011) 2.27

Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol (2011) 2.24

Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J Cell Mol Med (2009) 2.13

Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc Natl Acad Sci U S A (2007) 2.10

Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov (2009) 2.10

Tumor pH and its measurement. J Nucl Med (2010) 2.08

The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr (2007) 2.07

Metabolism of [U-13 C]glucose in human brain tumors in vivo. NMR Biomed (2012) 2.06

Mitochondrial p32 protein is a critical regulator of tumor metabolism via maintenance of oxidative phosphorylation. Mol Cell Biol (2010) 2.05

Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proc Natl Acad Sci U S A (2007) 2.01

Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br J Cancer (2007) 2.00

HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J Bioenerg Biomembr (2007) 2.00

Cancer as a metabolic disease. Nutr Metab (Lond) (2010) 1.98

Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH. Neoplasia (2006) 1.98

Tumor metabolism: cancer cells give and take lactate. J Clin Invest (2008) 1.97

Cancer evolution is associated with pervasive positive selection on globally expressed genes. PLoS Genet (2014) 1.94

Disrupting proton dynamics and energy metabolism for cancer therapy. Nat Rev Cancer (2013) 1.93

Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. Cell Metab (2014) 1.92

The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasion. Cancer Res (2009) 1.92

The tumor microenvironment and metastatic disease. Clin Exp Metastasis (2008) 1.91

Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer (2006) 1.91

Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta (2010) 1.88

Catabolic efficiency of aerobic glycolysis: the Warburg effect revisited. BMC Syst Biol (2010) 1.88

Identification of small molecule inhibitors of pyruvate kinase M2. Biochem Pharmacol (2009) 1.86

Metabolic Heterogeneity in Human Lung Tumors. Cell (2016) 1.86

Environment Impacts the Metabolic Dependencies of Ras-Driven Non-Small Cell Lung Cancer. Cell Metab (2016) 1.85

Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology (2013) 1.85

Multi-compound polarization by DNP allows simultaneous assessment of multiple enzymatic activities in vivo. J Magn Reson (2010) 1.84

Natural D-glucose as a biodegradable MRI contrast agent for detecting cancer. Magn Reson Med (2012) 1.84

The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia. Cell Cycle (2008) 1.83

Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis? J Bioenerg Biomembr (2007) 1.83

Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther (2011) 1.81

Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res (2010) 1.81

Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ (2010) 1.79

Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget (2012) 1.77

Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A (2013) 1.76

Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. Semin Cancer Biol (2008) 1.76

Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression. Aging (Albany NY) (2011) 1.74

Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell (2013) 1.73

Mitochondria as signaling organelles in the vascular endothelium. Proc Natl Acad Sci U S A (2006) 1.72

Low-field paramagnetic resonance imaging of tumor oxygenation and glycolytic activity in mice. J Clin Invest (2008) 1.71

Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr (2012) 1.70

Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol (2015) 1.68

Imaging pH and metastasis. NMR Biomed (2011) 1.67

Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood (2008) 1.67

CPEB regulation of human cellular senescence, energy metabolism, and p53 mRNA translation. Genes Dev (2008) 1.66

Genome-scale metabolic modeling elucidates the role of proliferative adaptation in causing the Warburg effect. PLoS Comput Biol (2011) 1.66

Amino Acids Rather than Glucose Account for the Majority of Cell Mass in Proliferating Mammalian Cells. Dev Cell (2016) 1.65

Understanding the pharmacological properties of a metabolic PET tracer in prostate cancer. Proc Natl Acad Sci U S A (2014) 1.65

Application of medical gases in the field of neurobiology. Med Gas Res (2011) 1.64

The genomic analysis of lactic acidosis and acidosis response in human cancers. PLoS Genet (2008) 1.60

An analogy between the evolution of drug resistance in bacterial communities and malignant tissues. Nat Rev Cancer (2011) 1.58

Proangiogenic contribution of adiponectin toward mammary tumor growth in vivo. Clin Cancer Res (2009) 1.58

Glucose metabolism attenuates p53 and Puma-dependent cell death upon growth factor deprivation. J Biol Chem (2008) 1.58

Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts. PLoS One (2009) 1.58

Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer (2013) 1.57

A microenvironmental model of carcinogenesis. Nat Rev Cancer (2008) 4.40

Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol (2006) 3.98

Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res (2006) 3.90

Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res (2009) 3.40

Adaptive therapy. Cancer Res (2009) 2.81

Radiomics: the process and the challenges. Magn Reson Imaging (2012) 2.65

Acidity generated by the tumor microenvironment drives local invasion. Cancer Res (2013) 2.63

Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia (2005) 2.17

Tumor pH and its measurement. J Nucl Med (2010) 2.08

Renal and systemic pH imaging by contrast-enhanced MRI. Magn Reson Med (2003) 2.05

High resolution pH(e) imaging of rat glioma using pH-dependent relaxivity. Magn Reson Med (2006) 1.97

Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol (2007) 1.94

The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasion. Cancer Res (2009) 1.92

Hitting multiple targets with multimeric ligands. Expert Opin Ther Targets (2004) 1.86

Responsive MRI agents for sensing metabolism in vivo. Acc Chem Res (2009) 1.84

Imaging pH and metastasis. NMR Biomed (2011) 1.67

Lanthanide-based time-resolved fluorescence of in cyto ligand-receptor interactions. Anal Biochem (2004) 1.66

Contributions of cell metabolism and H+ diffusion to the acidic pH of tumors. Neoplasia (2003) 1.63

Stability of FDG-PET Radiomics features: an integrated analysis of test-retest and inter-observer variability. Acta Oncol (2013) 1.62

Metabolic changes during carcinogenesis: potential impact on invasiveness. J Theor Biol (2006) 1.59

Novel targeting strategy based on multimeric ligands for drug delivery and molecular imaging: homooligomers of alpha-MSH. Bioorg Med Chem Lett (2004) 1.58

Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol (2003) 1.57

Quantitative imaging in cancer evolution and ecology. Radiology (2013) 1.55

Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther (2005) 1.54

Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia (2005) 1.54

Lateral phase separation in lipid-coated microbubbles. Langmuir (2006) 1.52

Of cancer and cave fish. Nat Rev Cancer (2011) 1.50

Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia (2005) 1.45

Acid treatment of melanoma cells selects for invasive phenotypes. Clin Exp Metastasis (2008) 1.44

Sweat but no gain: inhibiting proliferation of multidrug resistant cancer cells with "ersatzdroges". Int J Cancer (2014) 1.44

Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm (2011) 1.42

Imaging the extracellular pH of tumors by MRI after injection of a single cocktail of T1 and T2 contrast agents. NMR Biomed (2011) 1.40

Determining suitable internal standards for mRNA quantification of increasing cancer progression in human breast cells by real-time reverse transcriptase polymerase chain reaction. Anal Biochem (2005) 1.38

Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents. Biochem Pharmacol (2003) 1.38

Chronic autophagy is a cellular adaptation to tumor acidic pH microenvironments. Cancer Res (2012) 1.38

Automated Delineation of Lung Tumors from CT Images Using a Single Click Ensemble Segmentation Approach. Pattern Recognit (2013) 1.36

Multiscale modelling of vascular tumour growth in 3D: the roles of domain size and boundary conditions. PLoS One (2011) 1.36

Heterobivalent ligands crosslink multiple cell-surface receptors: the human melanocortin-4 and delta-opioid receptors. Angew Chem Int Ed Engl (2008) 1.36

A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33

Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. Neoplasia (2002) 1.32

Synthesis and evaluation of bivalent NDP-alpha-MSH(7) peptide ligands for binding to the human melanocortin receptor 4 (hMC4R). Bioconjug Chem (2007) 1.31

Systemic buffers inhibit carcinogenesis in TRAMP mice. J Urol (2012) 1.28

Development of a lanthanide-based assay for detection of receptor-ligand interactions at the delta-opioid receptor. Anal Biochem (2005) 1.25

Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia (2008) 1.23

Thermostability of firefly luciferases affects efficiency of detection by in vivo bioluminescence. Mol Imaging (2004) 1.23

A stimulus-responsive contrast agent for ultrasound molecular imaging. Biomaterials (2007) 1.22

Reduction of metastasis using a non-volatile buffer. Clin Exp Metastasis (2011) 1.21

Enhanced targeting with heterobivalent ligands. Mol Cancer Ther (2009) 1.21

Evolutionary dynamics of cancer prevention. Nat Rev Cancer (2010) 1.20

Rigid linkers for bioactive peptides. Bioconjug Chem (2006) 1.19

Expression-driven reverse engineering of targeted imaging and therapeutic agents. Expert Opin Ther Targets (2003) 1.19

Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings. Clin Nucl Med (2013) 1.19

Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Res (2012) 1.19

The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging. Clin Cancer Res (2005) 1.17

DNA and polylysine adsorption and multilayer construction onto cationic lipid-coated microbubbles. Langmuir (2007) 1.16

Gold nanorods targeted to delta opioid receptor: plasmon-resonant contrast and photothermal agents. Mol Imaging (2008) 1.15

Redox-sensitive contrast agents for MRI based on reversible binding of thiols to serum albumin. Magn Reson Med (2006) 1.14

MRI-measured water mobility increases in response to chemotherapy via multiple cell-death mechanisms. NMR Biomed (2007) 1.14

Lanthanide-based luminescent assays for ligand-receptor interactions. Life Sci (2005) 1.13

Animal anaesthesia for in vivo magnetic resonance. NMR Biomed (2003) 1.11

Targeting the metabolic microenvironment of tumors. Adv Pharmacol (2012) 1.11

Promise and progress for functional and molecular imaging of response to targeted therapies. Pharm Res (2007) 1.11

Characterization of breast cancers and therapy response by MRS and quantitative gene expression profiling in the choline pathway. NMR Biomed (2009) 1.10

Design, synthesis, and biological studies of efficient multivalent melanotropin ligands: tools toward melanoma diagnosis and treatment. J Med Chem (2011) 1.10

Noninvasive detection of breast cancer lymph node metastasis using carbonic anhydrases IX and XII targeted imaging probes. Clin Cancer Res (2011) 1.10

Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer. Mol Cancer Ther (2008) 1.10

In vivo magnetic resonance imaging of tissue pH using a novel pH-sensitive contrast agent, GdDOTA-4AmP. Acad Radiol (2002) 1.06

Current advances in mathematical modeling of anti-cancer drug penetration into tumor tissues. Front Oncol (2013) 1.05

Molecular imaging and targeted therapies. Biochem Pharmacol (2010) 1.05

Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas. PLoS One (2013) 1.03

Effects of linker length and flexibility on multivalent targeting. Biomacromolecules (2008) 1.02

Solid-Phase Synthesis of Heterobivalent Ligands Targeted to Melanocortin and Cholecystokinin Receptors. Int J Pept Res Ther (2008) 1.02

Development of an orthotopic human pancreatic cancer xenograft model using ultrasound guided injection of cells. PLoS One (2011) 1.01

A mammaglobin-A targeting agent for noninvasive detection of breast cancer metastasis in lymph nodes. Cancer Res (2010) 1.01

Uncovering of intracellular water in cultured cells. Magn Reson Med (2005) 1.00

Cell-specific targeting by heterobivalent ligands. Bioconjug Chem (2011) 1.00

Design, synthesis, and validation of a branched flexible linker for bioactive peptides. J Org Chem (2007) 0.98

Test-retest reproducibility analysis of lung CT image features. J Digit Imaging (2014) 0.98

Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo. NMR Biomed (2005) 0.97

A mathematical model of tumour and blood pHe regulation: The HCO3-/CO2 buffering system. Math Biosci (2010) 0.97

A semiautomatic CT-based ensemble segmentation of lung tumors: comparison with oncologists' delineations and with the surgical specimen. Radiother Oncol (2012) 0.96

Acid-mediated tumor proteolysis: contribution of cysteine cathepsins. Neoplasia (2013) 0.96

Response of choline metabolites to docetaxel therapy is quantified in vivo by localized (31)P MRS of human breast cancer xenografts and in vitro by high-resolution (31)P NMR spectroscopy of cell extracts. Magn Reson Med (2007) 0.95

Free Base Lysine Increases Survival and Reduces Metastasis in Prostate Cancer Model. J Cancer Sci Ther (2011) 0.94

A quantitative theoretical model for the development of malignancy in ductal carcinoma in situ. J Theor Biol (2009) 0.94

Heterobivalent ligands target cell-surface receptor combinations in vivo. Proc Natl Acad Sci U S A (2012) 0.94

Squalene-derived flexible linkers for bioactive peptides. Bioorg Med Chem Lett (2007) 0.93

Optimization of time-resolved fluorescence assay for detection of europium-tetraazacyclododecyltetraacetic acid-labeled ligand-receptor interactions. Anal Biochem (2009) 0.93

Hypoxia and the presence of human vascular endothelial cells affect prostate cancer cell invasion and metabolism. Neoplasia (2007) 0.92

A solanesol-derived scaffold for multimerization of bioactive peptides. J Org Chem (2010) 0.91

Identification of novel pancreatic adenocarcinoma cell-surface targets by gene expression profiling and tissue microarray. Biochem Pharmacol (2010) 0.90

A sucrose-derived scaffold for multimerization of bioactive peptides. Bioorg Med Chem (2011) 0.90

Solid-phase synthetic strategy and bioevaluation of a labeled delta-opioid receptor ligand Dmt-Tic-Lys for in vivo imaging. Org Lett (2009) 0.90

Specificity and mobility of biomacromolecular, multivalent constructs for cellular targeting. Biomacromolecules (2007) 0.89

Development of melanoma-targeted polymer micelles by conjugation of a melanocortin 1 receptor (MC1R) specific ligand. J Med Chem (2011) 0.89

Imaging biomarkers to monitor response to the hypoxia-activated prodrug TH-302 in the MiaPaCa2 flank xenograft model. Magn Reson Imaging (2012) 0.89

Synthesis and characterization of a Eu-DTPA-PEGO-MSH(4) derivative for evaluation of binding of multivalent molecules to melanocortin receptors. Bioorg Med Chem Lett (2010) 0.89

Synthesis and characterization of time-resolved fluorescence probes for evaluation of competitive binding to melanocortin receptors. Bioorg Med Chem (2013) 0.89

Evaluation of LDH-A and glutaminase inhibition in vivo by hyperpolarized 13C-pyruvate magnetic resonance spectroscopy of tumors. Cancer Res (2013) 0.87

Vascular measurements correlate with estrogen receptor status. BMC Cancer (2014) 0.87